NAMZARIC (memantine hydrochloride and donepezil hydrochloride) by AbbVie is medications: memantine hydrochloride and donepezil hydrochloride. Approved for moderate to severe dementia of the alzheimer's type in patients stabilized on 10 mg of donepezil hydrochloride once daily. First approved in 2014.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
NAMZARIC is a fixed-dose combination of memantine hydrochloride and donepezil hydrochloride approved for moderate to severe Alzheimer's disease dementia. It combines two complementary mechanisms: memantine acts as an NMDA receptor antagonist to modulate glutamate-mediated excitotoxicity, while donepezil enhances cholinergic function through acetylcholinesterase inhibition. The product is indicated for patients already stabilized on 10 mg donepezil daily, offering convenient once-daily extended-release dosing. Neither component halts neurodegeneration, but both address symptomatic cognitive decline.
medications: memantine hydrochloride and donepezil hydrochloride. Each of those medications is postulated to have a different mechanism in Alzheimer's disease. Memantine Persistent activation of central nervous system NMDA receptors by the excitatory amino acid glutamate has been hypothesized to…
Worked on NAMZARIC at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~4 years — strategic planning for patent cliff underway
$108M Medicare spend — this is a commercially significant brand
NAMZARIC supports commercial roles including brand management, market access, and specialty field teams focused on neurology and geriatrics. Medical science liaisons (MSLs) specializing in dementia care and cognitive neurobiology are valuable assets for this product. Currently, zero open positions are linked to this product in available employment data, suggesting the commercial team infrastructure is established and stable.